| 产品详情 |
| Edit |   |
|---|
| Product Name | Human cFGF-21 ELISA Assay Kit |
|---|
| Description | This Eagle Biosciences Human C-Terminal ELISA Assay Kit is designed, developed and produced for the quantitative measurement of human C-terminal FGF-21 in serum and EDTA-plasma sample. The assay utilizes the two-site ``sandwich'' technique with two selected antibodies that bind to different epitopes of human FGF-21. One of the antibodies specifically binds to the C-terminal human FGF-21 (175-181) and the other is to the multi-epitopes of mid-regional and N-terminal human FGF-21. Assay calibrators, controls and patient samples are added directly to wells of a microplate that is coated with an anti-human FGF-21 (175-181) specific antibody. After the first incubation period, a horseradish peroxidase-conjugated anti-human FGF-21 polyclonal antibody is added to each well. After the second incubation period, the antibody on the wall of microtiter well captures human C-terminal FGF-21 in the sample and further forms ``sandwich'' with the tracer antibody. Unbound proteins in each microtiter well are washed away. An immunocomplex of ``anti-FGF-21 antibody --- human C-terminal FGF-21 --- HRP-conjugated tracer antibody'' is formed. The unbound tracer antibody is removed in the subsequent washing step. For the detection of this immunocomplex, the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to human C-terminal FGF-21 on the wall of the microtiter well is directly proportional to the amount of C-terminal FGF-21 in the sample. A calibrator curve is generated by plotting the absorbance versus the respective human C-terminal FGF-21 concentration for each calibrator on point-to-point or 4 parameter curve fit. The concentration of human C-terminal FGF-21 in test samples is determined directly from this calibrator curve. Sample Types: serum, EDTA plasma. Range: 54 - 2100 pg/mL. Sensitivity: 3.7 pg/mL. Time: 2.5 hours • Fibroblast Growth Factor 21 (FGF-21) belongs to the FGF-19 subfamily, which includes FGF-19, FGF-21 and FGF-23. The FGF-19 family members are potent endocrine hormones in the regulation of a diverse physiological homeostasis. The intact FGF-21 is a small protein comprising 181 amino acids. Administration of recombinant FGF-21 lowered plasma glucose and insulin levels, reduced hepatic and circulating triglycerides and cholesterol levels, and improved insulin sensitivity, energy expenditure, hepatic steatosis and obesity in a range of insulin-resistant animal models. The physiological functions of FGF-21 are relied on the intact molecular structure and amino acid sequence in its N-terminal and C-terminal region. The C-terminal non-truncated FGF-21 is a potent cell membrane β-Klotho binder. Whereas, a C-terminal truncated FGF-21 (1-170) is a potent inhibitor that competitively inhibits the biological activity of intact FGF-21 (1-181). Therefore, it is important to measure the circulation intact FGF-21 level in the assessment of the physiological and pathophysiological condition. An assay that determines the fragment of the FGF-21 might overestimate the biological activity of the protein in test sample. Circulation FGF-21 is a biomarker and its levels are increased in patients with nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, gestational diabetes and obesity. An increase of circulating FGF-21 is also found in patients with Cushing's syndrome, patients with lipodystrophy induced by HIV-1 and patients with chronic renal disease or end-stage renal disease (ESRD). |
|---|
| Size | 1 x 96 well |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | cFGF-21, Fibroblast Growth Factor 21, FGF-21 |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | CTF31-K01 |
|---|
| Price | |
|---|
| Order / More Info | Human cFGF-21 ELISA Assay Kit from EAGLE BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|